
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a life sciences manufacturer with a strong presence in the protein sciences and diagnostics and genomics segments, with a significant portion of its revenue coming from the United States and other global markets. The company has a solid track record of successful regulatory processes and its recent acquisition by Merck KGaA is not expected to face any major antitrust issues. Although there are some potential risks to consider, such as acquisition and cell therapy progress, Bio-Techne's strong position in the biotech market and its strategic initiatives make it well positioned to benefit from the expected rebound in demand and potential future growth opportunities.
Bears say
Bio-Techne is a global company with a strong presence in the life sciences market, but operational challenges and risks, such as potential share loss and reliance on cell therapy development, make its stock a risky investment. Additionally, the company's mixed track record with acquisitions adds uncertainty. While Bio-Techne continues to find opportunities for self-improvement, its growth may be slow to rebound, and current regulatory conditions suggest a sector performance for the future.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares